Oncopeptides in focus
Oncopeptides is a global biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat hematological diseases.
Oncopeptides vision is to bring hope to patients through passionate people, innovative science and transformative medicines.
We are science driven, entrepreneurial, and committed to bringing innovation to patients with diseases where there is a clear unmet need.
Oncopeptides first drug Pepaxti has been granted full approval for treatment of adult patients with multiple myeloma in Europe. Pepaxto has received an accelerated approval in the US, but is currently not marketed there.
Our innovative drug is based on the Peptide Drug Conjugate (PDC) platform, and offers patients robust efficacy, reduces treatment burden and maintains quality of life.
Our pipeline includes drug candidates built on the PDC platform and the Small Polypeptide based Killer Engagers (SPiKE) platform.
We have a values-driven culture and inclusive organization that welcomes people with diverse backgrounds and perspectives.
We are headquartered in Stockholm, Sweden, have 55 coworkers and and a modern pre-clinical drug development facility in Solna, outside Stockholm.
Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.
Journey of innovation
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions.
The full marketing authorization of Pepaxti in Europe sets the stage for the strategic direction of Oncopeptides and enables us to give patients with multiple myeloma access to an innovative drug, that may reduce treatment burden and improve quality of life.
Oncopeptides’ corporate governance has, prior to the listing on Nasdaq Stockholm, been governed by the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)), the Swedish Annual Accounts Act (Sw. årsredovisningslagen (1995:1554)) and other applicable laws and regulations, the Company’s articles of association and internal policy documents.